MRD-Guided PRaG 3.0 Therapy for HER-2 Positive Cervical Adenocarcinoma: A Case of Complete Remission

A cervical adenocarcinoma case combines imaging follow-up with circulating tumor DNA monitoring.

Diseases & Research · May 8, 2025
Original authors: Junjun Zhang, Yuehong Kong, Meiling Xu, Tingting Fu, Guangqiang Chen, Zhihui Hong, Hong Zhang, Xiaoxiao Dai, Yifu Ma, Xiangrong Zhao, Chenyang Zhang, Rongzheng Chen, Pengfei Xing, Liyuan Zhang

Case report: an individual observation, not an estimate of how well the treatment works for other patients.

Who was studied?

A patient with refractory advanced cervical adenocarcinoma and HER2 immunohistochemistry 1+ expression.

What does the publication report?

Complete remission was reported after 2 cycles and maintained through 16 additional cycles. Circulating tumor DNA and lymphocyte measurements accompanied follow-up.

Safety findings

The abstract reports no significant side effects but does not provide a complete graded toxicity table.

How should we interpret it?

A single case cannot establish response rates or validate an MRD-guided decision strategy.

Read the original source

This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.

MRD-Guided PRaG 3.0 Therapy for HER-2 Positive Cervical Adenocarcinoma: A Case of Complete Remission · DOI: 10.54457/DR.202502001

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.